Mortaparibs (Mortaparib, Mortaparib<sup>Plus</sup>, and Mortaparib<sup>Mild</sup>) are chemical inhibitors of mortalin isolated by cell-based two-way screening involving (i) a shift in the mortalin staining pattern from perinuclear (characteristics of cancer cells) to pancytoplasmic (characteristics of normal cells) and (ii) the nuclear enrichment of p53. The gene discussed is HSPA9; the disease is cancer.